An investigational RNAi therapeutic targeting factor XII (ALN-F12) for the treatment of hereditary Angioedema
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A series of GalNAc-siRNA conjugates were established to treat a variety of GARDs with the liver as the target organ.
“A series of GalNAc-siRNA conjugates were established in recent years to treat a variety of GARDs with the liver as the target organ (Table 1).[64, 68, 79, 80]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [79]
Cited by
Sorted by citations
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82 · see citing works
Emerging Therapies in Hereditary Angioedema
Chen, M., & Riedl, M. A. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.03.003 · Cited by 29 · see citing works
Hereditary angioedema: examining the landscape of therapies and preclinical therapeutic targets
Farkas, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1608949 · Cited by 21 · see citing works
Heestermans, M., & van Vlijmen, B. J. M. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0130-8 · Cited by 9 · see citing works
Investigational drugs in phase I and phase II clinical trials for hereditary angioedema
Farkas, H., Debreczeni, M. L., & Kőhalmi, K. V. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415325 · Cited by 8 · see citing works
- Authors
- Akinc, A., Liu, J., Qin, J., Castoreno, A., Schlegel, M., Maier, M., Fitzgerald, K., & Meyers, R.
- Affiliations
- Alnylam Pharmaceuticals (United States) (US)
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 137
- Issue
- 2
- Pages
- AB254
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2338704051
- Cited by
- 5
- References
- 0
- Citations by year
- 2019: 2 · 2017: 3
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hereditary angioedema, factor XII, RNA interference, siRNA therapeutics, C1 inhibitor deficiency, bradykinin, vascular permeability, captopril, Evans blue, prophylaxis, dose-response relationship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
